IGI Logo

Zydus Lifesciences is currently trading at Rs. 365.60, up by 2.50 points or 0.69% from its previous closing of Rs. 363.10 on the BSE.

The scrip opened at Rs. 367.00 and has touched a high and low of Rs. 369.00 and Rs. 361.25 respectively. So far 31125 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 331.00 on 07-Mar-2022.

Last one week high and low of the scrip stood at Rs. 376.60 and Rs. 348.85 respectively. The current market cap of the company is Rs. 37335.89 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 15.44% and 9.69% respectively.

Zydus Lifesciences is planning to manufacture and supply Sagent’s Caffeine Citrate Oral Solution in the strength of 60 mg per 3 mL (20 mg per mL) Single-dose Vial (US RLD: CAFCIT) from its injectables facility at Jarod, Gujarat, India. The company received the Prior Approval Supplement (PAS) approval from the US Food and Drug Administration (USFDA), which allows for a site transfer and manufacturing of the drug at Jarod.

This product is indicated for the short-term treatment of a breathing problem (Apnea) in premature infants. Caffeine blocks certain proteins (adenosine receptors) which leads to improved breathing in these infants. Sagent Pharmaceuticals, Inc. (Sagent), a Nichi-Iko Group Company, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing, and marketing pharmaceutical products for the North American market, with a specific emphasis on injectables.

Zydus Lifesciences is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.